Telomir Pharmaceuticals, Inc. (TELO) - 10-K Summary
Business Context and Reporting Period
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage biopharmaceutical company incorporated in Florida. The company is focused on the development of Telomir-1, a novel oral small molecule metal ion regulator designed to extend telomere caps, maintain cellular balance, and combat oxidative stress. The filing covers the fiscal year ended December 31, 2024. The company operates with a virtual office model and relies on third-party contractors for research and development.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(16.53) million | $(13.07) million |
| Operating Expenses | $12.24 million | $3.94 million |
| Research & Development | $2.24 million | $1.57 million |
| General & Administrative | $9.64 million | $0.60 million |
| Cash Flow from Operations | $(5.07) million | $(3.86) million |
| Cash Flow from Financing | $6.34 million | $3.86 million |
| Cash and Equivalents (Year End) | $1.27 million | $0.001 million |
| Accumulated Deficit | $(30.60) million | $(14.06) million |
Material Changes vs. Prior Period
- Expense Surge: Total operating costs increased by approximately 210% from 2023 to 2024, driven primarily by a $9.0 million increase in General and Administrative (G&A) expenses. This spike was largely due to $6.7 million in stock-based compensation for new options granted in 2024 and $1.2 million in payroll expenses following the IPO.
- Related Party Costs: Related party travel costs (aircraft lease) decreased significantly from $1.77 million in 2023 to $0.37 million in 2024, as the lease was terminated in April 2024.
- Interest Expense: Interest expense rose to $4.34 million in 2024 compared to $1.64 million in 2023, primarily due to the amortization of debt issuance costs related to a line of credit that expired upon the completion of the IPO.
- Debt Conversion: In 2023, the company recorded a $7.49 million loss on the extinguishment of debt due to the conversion of related party debt into common stock. No such conversions occurred in 2024.
Guidance, Outlook, and Risks
- Going Concern: The company has raised substantial doubt about its ability to continue as a going concern. With cash of approximately $1.3 million as of December 31, 2024, management expects funds to be sufficient only until midway through the second quarter of 2025. Additional financing is required to continue operations.
- Development Timeline: Safety studies are scheduled for Q2 2025. The company targets an Investigational New Drug (IND) submission in Q4 2025, with first-in-human trials anticipated in early 2026.
- Intellectual Property: Telomir-1 rights are licensed from MIRALOGX, LLC. The license covers U.S. human and veterinary applications but excludes foreign jurisdictions. The company pays an 8% royalty on net sales but has no upfront or milestone payments.
- Risks: Key risks include the speculative nature of pre-clinical drug development, reliance on third-party manufacturers and CROs, potential failure to secure additional funding, and the concentration of ownership (founder's trusts control over 70% of shares).
Investor Verification Checklist
- Liquidity Runway: Verify the company's ability to secure the necessary capital to bridge the gap between current cash reserves ($1.27M) and the projected funding needs for Q2 2025.
- Related Party Transactions: Review the terms of the new $5 million unsecured Promissory Note with the Starwood Trust and the $1.0 million stock purchase agreement with the same entity.
- Stock-Based Compensation: Assess the impact of the $6.9 million stock-based compensation expense on future dilution and cash burn.
- Pre-Clinical Data: Scrutinize the validity and reproducibility of the pre-clinical studies (zebrafish, nematode, cell lines) cited as evidence for Telomir-1's efficacy in treating Type 2 Diabetes, Wilson's disease, and aging.
- Management Continuity: Note the transition of executive leadership in 2024, including the appointment of a new CEO (Erez Aminov) and CFO (Michelle Yanez), and the passing of the former CEO.